Comments
BL Research Bureau
Supriya Lifescience (Supriya) IPO opened at ₹425 per share, a 55 per cent premium to the issue price of ₹274. Subsequently, it has given up some of the gains, and at the time of writing, this was trading at ₹400 a 46 per cent premium. The strong listing gains of the IPO have pushed the valuations of the API player to the upper range of industry multiples at 23.7 times FY21 earnings compared to the modest 16.2 times at the time of IPO.
Related Stories
Supriya Lifescience IPO – Should you invest?
It is valued at 16.2 times FY21 EPS and will have market cap of around ₹2,200 crore at issue priceWe earlier recommended subscribing to the IPO in our note published in the Portfolio edition dated December 19. At the IPO valuation of 16.2 times FY21 EPS, it was reasonably valued, giving scope for upside given its strong financial profile, growth prospects and potential positive surprises on the macro-front (demand moving from China and strong domestic environment).
Even as Supriya’s operational performance can be expected to sustain, the current valuation post listing premium leaves little margin of safety for company-specific execution risks and broader market risks. Hence, we recommend investors book profits now at the current price and consider re-entering on future corrections.
Business performance
Supriya Lifescience Limited (SLL) is an API manufacturer (Active Pharmaceutical Ingredients) with a portfolio of 38 APIs. It has demonstrated strong operational performance, backed by established presence in three export molecules (share of 30-65 of FY21 exports from India in these molecules); backward integrated model extending to n-7 or 8 stage of production in 12 molecules; and by increasing presence in regulated markets of Europe, US and China. This is reflected in the 17 per cent revenue CAGR in FY19-21 with EBITDA margins scaling up to 43 per cent in FY21 (from 23 per cent in FY19). The company’s, margins have gained more from backward integration and regulated market expansion.
The company operates from Parshuram Lote, Maharashtra, with a capacity of 547 KL/day, which increased in the last year from 332 KL/day. The IPO proceeds of ₹92 crore (of the fresh proceeds ₹200 crore) will be utilised for developing land acquired near the current facility for new therapy lines, including decongestants and anti-gout medication.
Going forward, investors must track the stickiness of the margin expansion in future earnings. Also, Supriya’s realisation from China +1 and government incentives for industry growth need to be monitored, which the company is optimistic and ideating upon.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.